Alaunos Therapeutics
TCRT
78 hedge funds and large institutions have $241M invested in Alaunos Therapeutics in 2013 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 37 increasing their positions, 8 reducing their positions, and 14 closing their positions.
363% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 8
52% more capital invested
Capital invested by funds: $159M → $241M (+$82M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
35% more call options, than puts
Call options by funds: $8.1M | Put options by funds: $5.99M
1% more funds holding
Funds holding: 77 → 78 (+1)
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TS
Third Security
Radford,
Virginia
|
+$11.4M |
| 2 |
State Street
Boston,
Massachusetts
|
+$9.18M |
| 3 |
Jennison Associates
New York
|
+$7.71M |
| 4 |
MP
MSD Partners
New York
|
+$6.35M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
-$834K |
| 2 |
GACM
Green Arrow Capital Management
New York
|
-$690K |
| 3 |
BL
Bolton LP
Greenwich,
Connecticut
|
-$494K |
| 4 |
ACI
AMP Capital Investors
Sydney,
Australia
|
-$453K |
| 5 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
-$394K |
TCRT Hedge Fund Activity: Q4 2013 in Review
78 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q4 2013, worth a combined $241M — up 52% from $159M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new TCRT positions and 14 closed out — a net gain of 1 holder — while 37 added to existing stakes and 8 trimmed.
The largest buyer was Third Security, adding an estimated $11.4M. The largest seller was Royce & Associates, cutting an estimated $834K.
- 78 institutional investors held Alaunos Therapeutics (TCRT) as of Q4 2013, up from 77 in Q3 2013.
- Funds reported $241M of Alaunos Therapeutics stock for Q4 2013, up 52% quarter-over-quarter.
- 15 funds opened new Alaunos Therapeutics positions in Q4 2013 and 14 closed out, a net change of +1 holder.
- The largest Alaunos Therapeutics buyer in Q4 2013 was Third Security, an estimated $11.4M added.
- The largest Alaunos Therapeutics seller in Q4 2013 was Royce & Associates, an estimated $834K sold.
Based on aggregated 13F filings for Q4 2013.